39631-30-6

Basic information

• Product Name: 2-(4-bromobenzoyl)hydrazinecarbothioamide
• Synonyms: 2-(4-bromobenzoyl)hydrazinecarbothioamide
• CAS NO: 39631-30-6
• Molecular Weight: 274.141
• Mol File: 39631-30-6.mol

Chemical Properties

• CAS DataBase Reference: 2-(4-bromobenzoyl)hydrazinecarbothioamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-bromobenzoyl)hydrazinecarbothioamide(39631-30-6)
• EPA Substance Registry System: 2-(4-bromobenzoyl)hydrazinecarbothioamide(39631-30-6)

Safety Data

• Hazardous Substances Data: 39631-30-6(Hazardous Substances Data)

Upstream product

• 333-20-0 potassium thioacyanate 
• 5933-32-4 4-bromobenzoic acid hydrazide 
• 619-42-1 4-methoxycarbonylphenyl bromide 
• 79-19-6 thiosemicarbazide 
• 586-75-4 4-chlorobenzoyl chloride 

Downstream Products

• 1276032-83-7 5-p-bromophenyl-3-(β-D-glucopyranosylthio)-1,2,4-triazole 
• 1276032-73-5 5-p-bromophenyl-3-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosylthio)-1,2,4-triazole 
• 1383783-65-0 4-(2-{[5-(4-bromophenyl)-4H-1,2,4-triazol-3-yl]thio}ethoxy)benzaldehyde 
• 39631-33-9 C₈H₆BrN₃S 
• 13178-12-6 5-(4-bromophenyl)-1,3,4-thiadiazol-2-amine 
• 106013-99-4 2-[5-(4-Bromo-phenyl)-4H-[1,2,4]triazol-3-ylsulfanyl]-1-(4-chloro-phenyl)-ethanone; hydrobromide 
• 106013-98-3 1-(4-Bromo-phenyl)-2-[5-(4-bromo-phenyl)-4H-[1,2,4]triazol-3-ylsulfanyl]-ethanone; hydrobromide 
• 106013-97-2 3-(p-Bromophenyl)-5-(p-methylphenacylthio)-s-triazole hydrobromide 
• 106014-00-0 2,6-Bis-(4-bromo-phenyl)-thiazolo[3,2-b][1,2,4]triazole 
• 106014-01-1 2-(4-Bromo-phenyl)-6-(4-chloro-phenyl)-thiazolo[3,2-b][1,2,4]triazole 
• 106020-12-6 2-(p-Bromophenyl)-5-(p-tolyl)thiazolo<3,2-b>-s-triazole 
• 106014-03-3 3-(p-Bromophenyl)-5-(p-tolyl)thiazolo<2,3-c>-s-triazole 
• 106014-02-2 2-(p-Bromobenzoyl)hydrazino-4-(p-tolyl)-thiazole hydrobromide 
• 39631-33-9 3-(p-Bromophenyl)-5-mercapto-s-triazole 

Relevant articles and documents

Design and development of 1,3,5-triazine-thiadiazole hybrids as potent adenosine A2A receptor (A2AR) antagonist for benefit in Parkinson's disease

Various studies showed adenosine A2A receptors (A2ARs) antagonists have profound therapeutic efficacy in Parkinsons Disease (PD) by improving dopamine transmission, thus being active in reversing motor deficits and extrapyramidal symptoms related to the disease. Therefore, in the presents study, we have showed the development of novel 1,3,5-triazine-thiadiazole derivative as potent A2ARs antagonist. In the radioligand binding assay, these molecules showed excellent binding affinity with A2AR compared to A1R, with significant selectivity. Results suggest, compound 7e as most potent antagonist of A2AR among the tested series. In docking analysis with A2AR protein model, compound 7e found to be deeply buried into the cavity of receptor lined via making numerous interatomic contacts with His264, Tyr271, His278, Glu169, Ala63, Val84, Ile274, Met270, Phe169. Collectively, our study demonstrated 1,3,5-triazine-thiadiazole hybrid as a highly effective scaffold for the design of new A2A antagonists.

1,3,4-Thiadiazole-Containing Azo Dyes: Synthesis, Spectroscopic Properties and Molecular Structure

Three series of azo dyes derived from 2-amino-5-aryl-1,3,4-thiadiazoles and aniline, N,N-dimethylaniline and phenol were synthesized in high yields by a conventional diazotization-coupling sequence. The chemical structures of the prepared compounds were confirmed by 1H-NMR, 13C-NMR, IR, UV-Vis spectroscopy, mass spectrometry and elemental analysis. In addition, the X-ray single crystal structure of a representative azo dye was presented. For explicit determination of the influence of a substituent on radiation absorption in UV-Vis range, time-dependent density functional theory calculations were performed.

Novel panaxadiol triazole derivatives induce apoptosis in HepG-2 cells through the mitochondrial pathway

In this study, we introduced 1, 2, 4-triazole groups into panaxadiol (PD) to obtain 18 panaxadiol triazole derivatives. Five cancer cells and one normal cell were evaluated for cytotoxicity by MTT assay. The results showed that most of the derivatives could inhibit cancer cell proliferation, and the anti-proliferative activity of compound A1 was the most significant. For HepG-2 cells, the IC50 value was 4.21 ± 0.54 μM, which was nearly 15 times higher than the activity of PD. Further studies showed that compound A1 could induce apoptosis in HepG-2 cells, and could enhance the expression of Cl-caspase-3, Cl-caspase-9 and Cl-PARP. Moreover, Western blot analysis showed that after treating HepG-2 cells with compound A1, the expression of p53 protein was increased and the ratio of Bax/Bcl-2 was gradually increased. The cytoplasmic Bax is then translocated to the mitochondria, causing the release of Cyt c protein. Therefore, the results indicate that compound A1 induces apoptosis through the mitochondrial pathway and can be used the potential to develop new anti-proliferative agents.

An efficient nonconventional glycerol-based solid acid catalyzed synthesis and biological evaluation of phosphonate conjugates of 1,2,4-triazole thiones

A series of diethyl (3-((5-aryl-1H-1,2,4-triazol-3-yl)thio)propyl)phos-phonates (7a-t) has been synthesized in excellent yields by coupling diethyl (3-bromopropyl)phosphonate and 5-aryl-1H- 1,2,4-triazol-3-thiones employing an efficient, green and nonconventional heterogeneous SO3Hcarbon catalyst derived from glycerol. In addition, a facile and green approach for the esterification of carboxylic acids by utilizing glycerol-based solid acid catalyst has been reported. Structures of the synthesized compounds were characterized by IR, NMR and HRMS studies. These triazole derivatives were screened for their in vitro cytotoxicity using the standard MTT (3-(4,5-dimethylthiazol-2- yl)-2,5-diphenyltetra-zolium bromide) assay against a panel of five different human cancer cell lines (HeLa: Cervix, A549: Lung, A375: Skin, MDA-MB-231: Breast and T98G: Brain). The antimicrobial activities of the synthesized compounds were investigated against four bacterial strains: Bacillus subtilis, Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa and three fungal strains: Aspergillus Niger, Aspergillus terreus, Aspergillus fumigatus. Preliminary results indicate that the compound 7f displayed maximum anticancer activity and the compounds 7d, 7e, 7f, 7m and 7q exhibited moderate antibacterial activity. The compounds 7g, 7h, 7o and 7p showed good antifungal activity with high inhibition zone diameter compared to the standard drug.

Magnetically Recyclable Nano-Fe 2O 3-Catalyzed Chemoselective Synthesis and Antioxidant Activity of Diethyl (3-((5-Aryl-1 H-1,2,4-triazol-3-yl)thio)propyl) phosphonates

An efficient, green, and chemoselective S-alkylation of 5-aryl-1H-1,2,4-triazole-3-thiones with diethyl (3-bromopropyl)phosphonate in water, catalyzed by nano-Fe2O3 under ligand-and base-free conditions, is reported. Clean reaction, less expensive catalyst, excellent yields, and easy workup are the advantages of the present method. The catalyst can be easily collected by a magnet and recycled without significant loss in catalytic activity. The newly synthesized compounds were screened for their antioxidant property by using 1,1-diphenyl-2-picrylhydrazyl (DPPH) scavenging assay. The majority of the compounds exhibited good antioxidant activity.

Synthesis and antibacterial activities of new S-glycosides bearing 1,2,4-triazole

Several new 5-aryl-3-(β-D-glucopyranosylthio)-1,2,4-triazoles have been synthesized. The structures of these new compounds were confirmed by 1H NMR, 13C NMR and elemental analyses.The antibacterial activities of the compounds were also evaluated.

Heterocyclic Systems Containing Bridgehead Nitrogen Atom: Part XLVIII - Syntheses of Thiazolo-s-triazoles and Thiazolo-s-triazoles

The reaction of 3-p-bromophenyl-5-mercapto-s-triazole (II) with α-halogenoketones in anhyd. ethanol gives ketones (IIIa-c) which undergo cyclization in the presence of PPA to furnish thiazolo-s-triazoles (IVa-c) and not the isomeric thiazolo